FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression
Semaglutide, marketed as Ozempic, recently became the first glucagon-like peptide 1 (GLP-1) receptor agonist approved by the US Food and Drug Administration (FDA) to reduce the risk of worsening kidney disease, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), a common complication of T2D.
Semaglutide, marketed as Ozempic, recently became the first glucagon-like peptide 1 (GLP-1) receptor agonist approved by the US Food and Drug Administration (FDA) to reduce the risk of worsening kidney disease, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), a common complication of T2D.
